Kronos Bio, Inc. (KRON)
0.8800
0.00 (0.00%)
Inactive · Last trade price on Jun 20, 2025
Company Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States.
It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease.
The company was incorporated in 2017 and is headquartered in San Mateo, California. As of June 20, 2025, Kronos Bio, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Kronos Bio, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Deborah Knobelman |
Contact Details
Address: 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 United States | |
| Phone | 650 781 5200 |
| Website | kronosbio.com |
Stock Details
| Ticker Symbol | KRON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001741830 |
| CUSIP Number | 50107A104 |
| ISIN Number | US50107A1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Deborah A. Knobelman Ph.D. | Interim Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and President |
| Joshua A. Kazam | Co-Founder and Director |
| David M. Tanen J.D. | Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | EFFECT | Notice of Effectiveness |
| Jun 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 20, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 20, 2025 | SCHEDULE 13D/A | Filing |
| Jun 20, 2025 | 25-NSE | Filing |
| Jun 20, 2025 | SC 14D9/A | Filing |